US Patent

US9358235 — Kinase modulation, and indications therefor

Method of Use · Assigned to Plexxikon Inc · Expires 2033-06-08 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using protein kinase inhibitors, such as Plexxikon's Pexidartinib Hydrochloride, to treat diseases associated with certain protein kinases.

USPTO Abstract

The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof.

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2606`	—	pexidartinib-hydrochloride
`U-2606`	—	pexidartinib-hydrochloride

Patent Metadata

Patent number: US9358235
Jurisdiction: US
Classification: Method of Use
Expires: 2033-06-08
Drug substance claim: No
Drug product claim: No
Assignee: Plexxikon Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.